OBJECTIVE: An unsolved problem in juvenile idiopathic arthritis (JIA) is to identify patients at special risk for relapse. It is important to adjust anti-inflammatory and immunosuppressive therapy to the children's actual disease activity especially in times of remission. Our aim was to analyze if the serum levels of MRP8/MRP14 are reliable predictive markers for the risk of relapse in clinically inactive juvenile idiopathic arthritis. METHODS: Serum concentrations of MRP8/MRP14 were determined by ELISA and correlated with laboratory and clinical parameters for disease activity in patients with JIA. 29 patients with changing disease activity were followed up for a mean time of 2.9 years. Two groups of patients--one before relapse (mean 3.7 months) but without clinical signs of disease reactivation, and one in remission for 12 further months--were compared. RESULTS: MRP8/MRP14 serum levels in patients before relapses were significantly higher than the levels in patients in stable remission for one year (662 ng/ml versus 395 ng/ml; p < 0.05). Using a cut-off for MRP8/MRP14 of 450 ng/ml the likelihood ratio for relapse was 3.7 (positive predictive value 80%), while no differences were found for C-reactive protein and erythrocyte sedimentation rate between the two groups. CONCLUSION: MRP8/MRP14 correlate with individual disease activity in patients with JIA. Our data suggest that local disease activity may be present even months before flares become clinically apparent. Serum levels of MRP8/MRP14 can give a hint as to clinically occult disease activity, in this way helping to adjust therapy in times of low disease activity.
OBJECTIVE: An unsolved problem in juvenile idiopathic arthritis (JIA) is to identify patients at special risk for relapse. It is important to adjust anti-inflammatory and immunosuppressive therapy to the children's actual disease activity especially in times of remission. Our aim was to analyze if the serum levels of MRP8/MRP14 are reliable predictive markers for the risk of relapse in clinically inactive juvenile idiopathic arthritis. METHODS: Serum concentrations of MRP8/MRP14 were determined by ELISA and correlated with laboratory and clinical parameters for disease activity in patients with JIA. 29 patients with changing disease activity were followed up for a mean time of 2.9 years. Two groups of patients--one before relapse (mean 3.7 months) but without clinical signs of disease reactivation, and one in remission for 12 further months--were compared. RESULTS:MRP8/MRP14 serum levels in patients before relapses were significantly higher than the levels in patients in stable remission for one year (662 ng/ml versus 395 ng/ml; p < 0.05). Using a cut-off for MRP8/MRP14 of 450 ng/ml the likelihood ratio for relapse was 3.7 (positive predictive value 80%), while no differences were found for C-reactive protein and erythrocyte sedimentation rate between the two groups. CONCLUSION:MRP8/MRP14 correlate with individual disease activity in patients with JIA. Our data suggest that local disease activity may be present even months before flares become clinically apparent. Serum levels of MRP8/MRP14 can give a hint as to clinically occult disease activity, in this way helping to adjust therapy in times of low disease activity.
Authors: Franak M Batliwalla; Wentian Li; Christopher T Ritchlin; Xiangli Xiao; Max Brenner; Teresina Laragione; Tianmeng Shao; Robert Durham; Sunil Kemshetti; Edward Schwarz; Rodney Coe; Marlena Kern; Emily C Baechler; Timothy W Behrens; Peter K Gregersen; Pércio S Gulko Journal: Mol Med Date: 2005 Jan-Dec Impact factor: 6.354
Authors: Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed Journal: Mol Med Date: 2007 Jan-Feb Impact factor: 6.354
Authors: Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405
Authors: Xuefeng B Ling; Jane L Park; Tanya Carroll; Khoa D Nguyen; Kenneth Lau; Claudia Macaubas; Edward Chen; Tzielan Lee; Christy Sandborg; Diana Milojevic; John T Kanegaye; Susanna Gao; Jane Burns; James Schilling; Elizabeth D Mellins Journal: Proteomics Date: 2010-11-23 Impact factor: 3.984
Authors: Helmut Wittkowski; Jasmin B Kuemmerle-Deschner; Judith Austermann; Dirk Holzinger; Raphaela Goldbach-Mansky; Katharina Gramlich; Peter Lohse; Thomas Jung; Johannes Roth; Susanne M Benseler; Dirk Foell Journal: Ann Rheum Dis Date: 2011-09-08 Impact factor: 19.103
Authors: Jason Michael Springer; Paul Monach; David Cuthbertson; Simon Carette; Nader A Khalidi; Carol A McAlear; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Gary Hoffman; Carol Langford; Thomas Hamilton; Dirk Foell; Thomas Vogl; Dirk Holzinger; Peter A Merkel; Johannes Roth; Rula A Hajj-Ali Journal: J Clin Rheumatol Date: 2018-10 Impact factor: 3.517